These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

339 related articles for article (PubMed ID: 12778472)

  • 1. Efficient mucosal delivery of the HIV-1 Tat protein using the synthetic lipopeptide MALP-2 as adjuvant.
    Borsutzky S; Fiorelli V; Ebensen T; Tripiciano A; Rharbaoui F; Scoglio A; Link C; Nappi F; Morr M; Buttó S; Cafaro A; Mühlradt PF; Ensoli B; Guzmán CA
    Eur J Immunol; 2003 Jun; 33(6):1548-56. PubMed ID: 12778472
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficient systemic and mucosal responses against the HIV-1 Tat protein by prime/boost vaccination using the lipopeptide MALP-2 as adjuvant.
    Borsutzky S; Ebensen T; Link C; Becker PD; Fiorelli V; Cafaro A; Ensoli B; Guzmán CA
    Vaccine; 2006 Mar; 24(12):2049-56. PubMed ID: 16406225
    [TBL] [Abstract][Full Text] [Related]  

  • 3. HIV mucosal vaccine: nasal immunization with gp160-encapsulated hemagglutinating virus of Japan-liposome induces antigen-specific CTLs and neutralizing antibody responses.
    Sakaue G; Hiroi T; Nakagawa Y; Someya K; Iwatani K; Sawa Y; Takahashi H; Honda M; Kunisawa J; Kiyono H
    J Immunol; 2003 Jan; 170(1):495-502. PubMed ID: 12496436
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The HIV-1 matrix protein p17 can be efficiently delivered by intranasal route in mice using the TLR 2/6 agonist MALP-2 as mucosal adjuvant.
    Becker PD; Fiorentini S; Link C; Tosti G; Ebensen T; Caruso A; Guzmán CA
    Vaccine; 2006 Jun; 24(25):5269-76. PubMed ID: 16713032
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Intranasal HIV-1-gp160-DNA/gp41 peptide prime-boost immunization regimen in mice results in long-term HIV-1 neutralizing humoral mucosal and systemic immunity.
    Devito C; Zuber B; Schröder U; Benthin R; Okuda K; Broliden K; Wahren B; Hinkula J
    J Immunol; 2004 Dec; 173(11):7078-89. PubMed ID: 15557206
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Induction of neutralizing antibodies and Th1-polarized and CD4-independent CD8+ T-cell responses following delivery of human immunodeficiency virus type 1 Tat protein by recombinant adenylate cyclase of Bordetella pertussis.
    Mascarell L; Fayolle C; Bauche C; Ladant D; Leclerc C
    J Virol; 2005 Aug; 79(15):9872-84. PubMed ID: 16014948
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mucosal delivery of the human immunodeficiency virus-1 Tat protein in mice elicits systemic neutralizing antibodies, cytotoxic T lymphocytes and mucosal IgA.
    Marinaro M; Riccomi A; Rappuoli R; Pizza M; Fiorelli V; Tripiciano A; Cafaro A; Ensoli B; De Magistris MT
    Vaccine; 2003 Sep; 21(25-26):3972-81. PubMed ID: 12922133
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mucosal immunity to HIV-1: systemic and vaginal antibody responses after intranasal immunization with the HIV-1 C4/V3 peptide T1SP10 MN(A).
    Staats HF; Nichols WG; Palker TJ
    J Immunol; 1996 Jul; 157(1):462-72. PubMed ID: 8683152
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effectiveness of intranasal immunization with HIV-gp160 and an HIV-1 env CTL epitope peptide (E7) in combination with the mucosal adjuvant LT(R192G).
    Morris CB; Cheng E; Thanawastien A; Cárdenas-Freytag L; Clements JD
    Vaccine; 2000 Mar; 18(18):1944-51. PubMed ID: 10699345
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Intranasal immunization with a plant virus expressing a peptide from HIV-1 gp41 stimulates better mucosal and systemic HIV-1-specific IgA and IgG than oral immunization.
    Durrani Z; McInerney TL; McLain L; Jones T; Bellaby T; Brennan FR; Dimmock NJ
    J Immunol Methods; 1998 Nov; 220(1-2):93-103. PubMed ID: 9839930
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Fibroblast-stimulating lipopeptide-1 as a potential mucosal adjuvant enhances mucosal and systemic immune responses to enterovirus 71 vaccine.
    Lin YL; Cheng PY; Chin CL; Huang LM; Lin SY; Chiang BL
    Vaccine; 2018 Jul; 36(29):4331-4338. PubMed ID: 29891349
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A novel adjuvant for mucosal immunity to HIV-1 gp120 in nonhuman primates.
    Yoshino N; Lü FX; Fujihashi K; Hagiwara Y; Kataoka K; Lu D; Hirst L; Honda M; van Ginkel FW; Takeda Y; Miller CJ; Kiyono H; McGhee JR
    J Immunol; 2004 Dec; 173(11):6850-7. PubMed ID: 15557179
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Codon optimization of the tat antigen of human immunodeficiency virus type 1 generates strong immune responses in mice following genetic immunization.
    Ramakrishna L; Anand KK; Mohankumar KM; Ranga U
    J Virol; 2004 Sep; 78(17):9174-89. PubMed ID: 15308713
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Mycoplasma-derived lipopeptide MALP-2 is a potent mucosal adjuvant.
    Rharbaoui F; Drabner B; Borsutzky S; Winckler U; Morr M; Ensoli B; Mühlradt PF; Guzmán CA
    Eur J Immunol; 2002 Oct; 32(10):2857-65. PubMed ID: 12355438
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cytokines as adjuvants for the induction of anti-human immunodeficiency virus peptide immunoglobulin G (IgG) and IgA antibodies in serum and mucosal secretions after nasal immunization.
    Bradney CP; Sempowski GD; Liao HX; Haynes BF; Staats HF
    J Virol; 2002 Jan; 76(2):517-24. PubMed ID: 11752142
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Anti-HIV-1 and anti-HBV immune responses in mice after parenteral and nasal co-administration of a multiantigenic formulation.
    Iglesias E; García D; Carrazana Y; Aguilar JC; Sánchez A; Gorobaya L; Blanco A
    Curr HIV Res; 2008 Sep; 6(5):452-60. PubMed ID: 18855656
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Intranasal priming with HIV DNA vaccine and systemic boosting with recombinant vaccinia induce vigorous immune responses: experiment with mice].
    Huang XG; Xu JQ; Ren L; Qiu C; Zhang N; Liu LX; Wan YM; Peng H; Shao YM
    Zhonghua Yi Xue Za Zhi; 2006 Nov; 86(44):3109-13. PubMed ID: 17313761
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Co-immunization with an HIV-1 Tat transduction peptide-rotavirus enterotoxin fusion protein stimulates a Th1 mucosal immune response in mice.
    Kim TG; Befus N; Langridge WH
    Vaccine; 2004 Jan; 22(3-4):431-8. PubMed ID: 14670325
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mucosal Priming with a Recombinant Influenza A Virus-Vectored Vaccine Elicits T-Cell and Antibody Responses to HIV-1 in Mice.
    Wang J; Shu T; Deng W; Zheng Y; Liao M; Ye X; Han L; He P; Zheng X; Li T; Feng Y; Hu F; Li P; Sun C; Chen L; Li F; Feng L
    J Virol; 2021 May; 95(12):. PubMed ID: 33789991
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Induction of systemic and mucosal cross-clade neutralizing antibodies in BALB/c mice immunized with human immunodeficiency virus type 1 clade A virus-like particles administered by different routes of inoculation.
    Buonaguro L; Visciano ML; Tornesello ML; Tagliamonte M; Biryahwaho B; Buonaguro FM
    J Virol; 2005 Jun; 79(11):7059-67. PubMed ID: 15890945
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.